Reports & Insights | Pharma Contract Manufacturing

Join a dedicated community at the Pharma Contract Manufacturing conference. We provide a secure environment to network, share insights, and overcome these hurdles. Our exclusive premium pass allows you to elevate your brand and forge lasting connections. Download now to see what our vendor-pass includes.

Explore the highlights from the 2025 Pharma Contract Manufacturing Conference!

Read more and discover:

• Audience overview and attending organisations
• Our esteemed 2025 speaker faculty
• Top sessions and key takeaways
• Testimonials from attendees
• Our 2024 sponsors
• What's next for Pharma Contract Manufacturing!

Interested in seeing who you will meet at Pharma Contract Manufacturing 2025? Download our 2025 attendee list to see who is joining us so far! At the event, we will bring industry leaders, experts, and innovators together from the CMO/CDMO and pharmaceutical industry, to engage in meaningful discussions and share best practices to tackle the challenges of today.

Present your boss with this customizable letter detailing the reasons why you should attend Pharma Contract Manufacturing 2026 from 23rd - 25th March 2026, in Berlin, Germany. Just download the letter template below, adjust as necessary (or edit as needed) and submit! We hope to welcome you there!

When you’re managing external manufacturing today, the pressure isn’t abstract; it’s daily, immediate, and growing. Capacity is tightening across sterile and biologics, global regulations are shifting faster than contracts can keep up, and geopolitical instability is reshaping where medicines can be made, sourced, and shipped.

This is exactly why the 2026 Pharma Contract Manufacturing Market Report was built: to give you the clarity, the benchmarks, and the competitive intelligence you need to make confident decisions in a market that isn’t standing still.

With expert commentary from Christian Simon, Head of Technical Transfer, External Manufacturing, Sanofi, and Philip Coetzee, Director, CMO Management, Daiichi Sankyo, they both share their insights on how to deliver reliability with less buffer, innovation with fewer resources, and agility with partners facing the same constraints you are.

Download to learn more about:

• Market Shifts You Need to Know: The global CMO/CDMO market is accelerating toward $319.6B by 2029, with biotech outsourcing growing more than 12% year-on-year.
• Risks You’re Navigating Every Day: Supply chain disruptions have increased by 38% in the past 12 months, driven by tariffs, sanctions, and regional realignments.
• What Makes Partnerships Actually Work in 2026: Strong alliances are built on shared visibility, structured communication, and joint planning, not just SLAs. Pharma teams that implement integrated review cycles with CMOs report 20-30% fewer delays and higher tech-transfer success.
• Innovation You Can’t Afford to Ignore: Digital twins and AI-based planning are improving cycle time by 15-40% in organisations already adopting them. Single-use systems continue to gain ground, reducing cleaning-related downtime by up to 60%.

If you’re operating in an environment where a single disruption – a delayed material, a missed forecast, an unexpected deviation – can ripple across your entire supply network. This report gives you the insights to anticipate those pressures, benchmark your partnerships, and build agility into your operations before the next disruption hits. Equip yourself with the intelligence to strengthen your CMO/CDMO relationships, negotiate with confidence, and protect your supply chain in the year ahead.

Download your copy now and stay ahead of the pressures reshaping pharma contract manufacturing.

If you’re managing external manufacturing partnerships today, you’re navigating more pressure than ever: shrinking capacity, sharper pricing tension, global uncertainties, and rising expectations for speed and quality.

This interview with Nico Orbello, Head SGD CDMO External Partnerships, Sandoz, was created for leaders exactly like you: those responsible for building relationships that can withstand complexity, absorb shocks, and still deliver for patients.

Nico shares his own thoughts on the realities you face daily: misaligned expectations, transparency gaps, communication breakdowns, and the constant balancing act between cost, quality, and long-term strategy. His insights offer a practical path forward, one grounded in trust, clarity, and collaboration that actually works when the pressure is real.

What you’ll learn when you download:

• How to strengthen trust with your CMO partners, even when capacity, pricing, or timelines are under strain.
• What transparency should look like in practice, and how it prevents delays, misalignment, and quality setbacks.
• The digital and smart manufacturing technologies that can make your operations more predictable, efficient, and audit-read

If you’re responsible for keeping supply flowing and partnerships stable, this interview will give you clarity, confidence, and actionable guidance you can use immediately. Download now!

If you manage external manufacturing, quality oversight, or supply continuity, you know the pressure: one late update, one missed signal, or one unspoken issue can derail timelines, compliance, and patient supply.

This interview with Marta Ferrer, External Supply QA Manager at Sandoz, is designed to support the challenges you face every day. Marta focuses on what leaders consistently tell us they need most: real-world clarity on how to build CMO relationships that stay transparent, aligned, and responsive under pressure.

Her insights help you anticipate risks earlier, strengthen communication, and identify when a partnership is positioning you for success, or quietly putting your supply chain at risk.

In this interview, you’ll gain practical guidance on:

• What to look for when assessing a CMO’s agility, responsiveness, and problem-solving behaviour.
• How to reduce your oversight burden by encouraging proactive communication instead of reactive updates.
• The digital and AI-enabled tools are already helping leaders reduce deviations and improve quality and reliability.
• What truly differentiates a long-term, dependable partnership from one that creates more work than value.

Download the interview now if you’re focused on strengthening supply continuity, ensuring audit readiness, and building partnerships that make your work easier not riskier.

Pharma-CMO alliances are facing unprecedented strain. Between geopolitical instability, capacity constraints, and rising quality expectations, the need for transparent, collaborative partnerships has never been more urgent.

In this exclusive interview, Kyriakos Kansos and George Ntortas, Partners, Fuliginous Management Consulting, share actionable strategies on how both pharma companies and CDMOs can move beyond transactional relationships and build alliances that are resilient, responsive, and future-ready.

Whether you manage external supply chains, strategic sourcing, or contract manufacturing partnerships, this conversation delivers real-world insights from decades of hands-on experience advising global manufacturing leaders.

Download this interview to learn more about:

• How alignment and communication across all functions, from QA to Finance, create the foundation for agile partnerships.
• Why shared visibility and ownership are the defining traits of resilient pharma–CMO alliances.
• How to balance tactical pressures with strategic goals to ensure today’s decisions strengthen tomorrow’s collaborations. 

Download the full interview now and discover how to turn fragile partnerships into agile, future-ready alliances.

The pharmaceutical industry is undergoing a rapid transformation, with Contract Manufacturing Organisations (CMOs) and Contract Development and Manufacturing Organisations (CDMOs) playing an increasingly vital role. Ahead of the Pharma Contract Manufacturing Summit 2025, Pharma IQ has put together a comprehensive market report, that delves into the trends, challenges, and opportunities shaping the future of pharmaceutical manufacturing.

Why Download This Report? This resource provides actionable insights for industry professionals navigating the complexities of pharmaceutical manufacturing. From building resilient supply chains to achieving sustainability goals, the report serves as a roadmap for optimising partnerships, operations, and compliance.

Download the report now to explore how you can stay ahead in a rapidly evolving market.

Key takeaways include: 

• Market Insights: Learn how the global CMO/CDMO market is projected to reach $310.9 billion by 2030, driven by demand for outsourcing and innovative drugs.
• Digital Transformation: Discover how AI, IoT, and smart manufacturing are revolutionising operational efficiency and regulatory compliance.
• Sustainability: Explore how green chemistry, carbon neutrality, and sustainable packaging are redefining industry standards.
• Geopolitical Complexities: Understand how regulations like the BIOSECURE Act and regional strategies are reshaping supply chain resilience.
• Innovation: Learn about the role of additive manufacturing, predictive analytics, and lights-out manufacturing in driving future growth.

When selecting partners, meeting stringent sustainability criteria along entire pharmaceutical supply chains has far-reaching environmental, economic and reputational benefits. Whilst adding a sustainability criteria to the bidding process is a positive one for driving more responsible operations across the entire pharmaceutical industry, it simultaneously amplifies the complexity of selecting a Contract Manufacturing Organization (CMO).

Unlock the report to delve into vital statistics and expert insights, covering:

• Stringent selection criteria: understand the pivotal role stringent criteria play in shaping responsible and sustainable partnerships
• Bottom line benefits: explore the tangible economic advantages that sustainable practices bring to the forefront of your pharmaceutical operations
• Technology for greener supply chains: navigate the latest innovations driving sustainability in pharmaceutical supply chains and stay ahead in the industry

Topped up with expert commentary from industry leaders: Philip Coetzee, Director CMO Management, Daiichi Sankyo and Gregory Vanderwinden, Associate Director – External Manufacturing EU, MSD.

Elevate your CMO selection process and lead the way towards a greener, more sustainable pharmaceutical future.  Access the report now.

Pharma IQ surveyed over 50 industry professionals, and accompanied by commentary from Ulrich Ruemenapp, Head of Launch Preparation at Bayer, this report will take an in-depth look at the most important components when selecting a CMO, the greatest risks when choosing to outsource and best practises for managing CMO networks.

Download the full report now >>>

Additional benefits to downloading the full report:

• Discover where the industry is at in its Pharma outsourcing journey
• The important factors to consider when selecting a CMO
• Find out more about how to reduce your external partner footprint
• Industry results for the greatest risks of outsourcing 
• Learn more about the characteristics that are most valued in a CMO
• Professional opinions on what areas are missing from the CMO market

As pharmaceutical businesses worldwide become more aware of the importance of meeting sustainability goals, it is inevitable that this will become a consideration when selecting a contract manufacturing organisation (CMO) or contract development and manufacturing organisation (CDMO). But it’s important to ensure that meeting sustainability goals when collaborating with external partners is genuine rather than just greenwashing.

That's why ahead of Pharma Contract Manufacturing 2024 we have collated exclusive insights on CMO Selection - Making Sustainability a Top Priority.

Access the infographic and dive into:

• The Top 5 considerations for sustainable CMO selection
• Key questions for the selection process
• Changing the culture strategy
• Examining your Scope 3 emissions
• Real-world examples of setting measurable targets
• Looking ahead: The big picture benefits

Join us at our free virtual panel ahead of our Annual Pharma Contract Manufacturing Conference. The panel will feature five distinguished industry experts, each bringing unique perspectives and deep expertise in their respective fields.

Together, they will explore emerging trends, challenges, and predictions for 2025, covering topics such as advancements in manufacturing technologies, regulatory shifts, supply chain strategies, and sustainability initiatives. You will gain actionable insights into how these developments could impact the industry landscape and your own operations.

Ahead of the Pharma Contract Manufacturing Summit 2023, Pharma IQ spoke exclusively to David Berry, Head of Digital Business Systems - Pharma, CPI about connecting automation to a QP dashboard at the MMIC, to help you discover new opportunities and solutions to your current pharma manufacturing challenges. 

Fill in the form below to access David's exclusive insights >>>

This exclusive interview with Philip Coetzee, Director of CMO Management at Daiichi Sankyo, provides a strategic look at the contract manufacturing landscape ahead of the Pharma Contract Manufacturing Summit 2025. 

This insightful interview with Sam Badawy, Quality Assurance Manager at Bayer, offers a comprehensive look at the challenges and strategies in maintaining quality assurance within pharma contract manufacturing. As regulatory landscapes shift and digital transformation accelerates, Sam Badawy discusses key strategies for building resilient CMO partnerships.

This exclusive interview with Dr. Ulrich Rümenapp, Senior Biotech Program Lead at Bayer AG, delves into the key strategies for biotech manufacturing success.

For pharma professionals involved in biotech manufacturing, this interview offers actionable insights on balancing quality, cost, and control. Gain expert perspectives on how to leverage specialised partnerships, maintain compliance, and navigate the complexities of biotech production for future-ready manufacturing strategies.

Explore effective strategies for successful CMO partnerships in pharma. Ahead of the upcoming Pharma Contract Manufacturing Summit, 26-27 March 2025, Pharma IQ spoke to Maik Talarczyk, Head PMO ESO at Sandoz, to discuss quality alignment, innovation, and future-proofing contract manufacturing partnerships in this exclusive interview.

The importance of selecting the right CMO/CDMO partnership is critical, as the benefits go beyond significant cost reduction, there is also the potential to improve and develop more strategies for pharmaceutical companies. But only if a mutually collaborative, open and trusting relationship is built.

Ahead of the Pharma Contract Manufacturing Summit 2025, we spoke exclusively to Federica Fraschetti, Associate Director, Focus Factory Leader – Bio ExM, MSD about the key do’s and don’ts when selecting a CMO, to help you find the right fit for your pharmaceutical company.

Download the full article here >>>

Due to the pandemic, the medical needs of populations worldwide are increasing and there is a huge demand for pharmaceutical products, causing CMOs and CDMOs to be increasingly sought after by pharmaceutical companies for their specialist equipment, facilities, labour force and cost-effective production. However, as large pharmaceutical companies start to develop in-house manufacturing capabilities, there is more and more competition between CMOs and CDMOs to prove they are the best partner.

Ahead of this year's Pharma Contract Manufacturing 2022 event, we spoke to Ulrich Rümenapp, Head of Launch Preparation and Coordination at Bayer AG, about the importance of maintaining positive partnerships with CMOs and CDMOs and build industry resilience.

Download the full interview now >>

Additional benefits to downloading the full interview:

• Discover how the last 18 months has impacted CMO and/or CDMO partnerships
• Learn about the greatest challenges of complex product manufacturing, and the top tips for overcoming these challenges
• Find out more about the benefits and opportunities of CMO and/or CDMO partnerships
• A summary of the key initiatives for maintaining positive CMO and/or CDMO partnerships over the next 2 years

It’s hardly surprising that pharma companies are changing the way they work with external partners, with increasing pressures on quality, cost and scalability determining not only which manufacturers the industry outsources to, but how many partners to take on.

With this in mind, Pharma IQ spoke with Simon Hendry, BD Director, Adare Pharmaceuticals, on the current challenges and best practices of streamlining external networks of CMOs. Hendry, speaks in-depth on the critical success factors you need to uncover in the selection process and how to manage emerging markets, all whilst ensuring quality isn’t compromised.

Download the full interview on the right >>

Other key benefits to downloading the full interview:

• Analysing what changes need to be made over the next 12-24 months to meet the main challenges of the industry
• Understanding the best practices for building a successful CMO partnership
• Exploring what criteria is most valuable to the industry when selecting a CDMO